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A B S T R A C T
Cas9 endonuclease from S. pyogenes is widely used to induce controlled double strand breaks (DSB) at desired ge-
nomic loci for gene editing. Here, we describe a droplet digital PCR (ddPCR) method to precisely quantify the ki-
netic of formation and 5′-end nucleolytic processing of Cas9-induced DSB in different human cells lines. Notably,
DSB processing is a finely regulated process, which dictates the choice between non-homologous end joining
(NHEJ) and homology directed repair (HDR). This step of DSB repair is also a relevant point to be taken into con-
sideration to improve Cas9-mediated technology. Indeed, by this protocol, we show that processing of Cas9-in-
duced DSB is impaired by CTIP or BRCA1 depletion, while it is accelerated after down-regulation of DNA-PKcs
and 53BP1, two DSB repair key factors. In conclusion, the method we describe here can be used to study DSB
repair mechanisms, with direct utility for molecularly optimising the knock-out/in outcomes in genome manipu-
lation.
1. Introduction
In mammalian cells, DSB lesions are faster repaired through NHEJ,
often resulting in small insertions or deletions [1,2]. This has been ex-
ploited by the CRISPR-Cas9 technology to generate gene knock-out. Al-
ternatively, in the S and G2 phases of the cell cycle, DSB can be ex-
tensively 5′-end nucleolytic processed (a phenomenon called DSB re-
section) by several endo- and exo-nucleases, in cooperation with heli-
cases, triggering HDR [3]. Notably, from yeast to mammals KU complex
and 53BP1 physically antagonize the DSB resection process [3,4]. Con-
currently, an intricate network of regulation suppresses DSB resection
in G1 cell cycle phase and in post-mitotic cells, thus preventing HDR.
Moreover, chromatin context influences the efficiency of induced DSB
formation and processing [5]. Once resection starts, DSB cannot be any
longer repaired by NHEJ, thus being a critical step to regulate NHEJ
and HDR outcomes. Remarkably, misregulation of the balance between
NHEJ and HDR triggers genome rearrangements and instability [3]. In-
deed mutations in genes encoding factors involved in DSB processing
(e.g. MRE11, BRCA1, CTIP) have been found in several cancer-prone in-
herited syndromes. As such, some of those factors are already studied
as attractive targets in cancer therapy [6,7]. Importantly, to edit a de-
sired locus in the genome with a donor template (e.g. gene sequence
substitution or single-codon modifications), resection at Cas9-induced
DSB (Cas9-DSB) is compulsory. Therefore, all the regulations and cellu-
lar aspects (such as cell cycle phase and chromatin context of the target
gene), that influence this crucial step of DSB repair, have to be taken in
to account to foresee the success of gene editing protocol. In this sce-
nario, a method to precisely quantify Cas9-DSB formation and process-
ing may be of great utility. In particular, in the literature an open ques-
tion is how Cas9-DSBs are resected, also considering the relative pro-
longed binding of the Cas9 protein on the substrate once DNA is cleaved
in vitro [8,9].
2. Material and methods
2.1. Cell culture, plasmids and treatments
U-2OS and HEK293T cells were grown in Dulbecco’s Modified Eagle
Medium (Gibco) containing 10% Fetal Bovine Serum (FBS; Gibco) and
1% Penicillin/Streptomycin (Euroclone). U-2OS-SEC (Stably Expressing
Cas9, under the tetracycline-inducible element) and HEK293-SEC (Sta-
bly Expressing Cas9, under the tetracycline-inducible element) were
available from Professor John Rouse (https://mrcppureagents.dundee.
ac.uk, see also [10]), and were grown in Dulbecco’s Modified Ea-
gle Medium (Gibco) containing 10% Fetal Bovine Serum (FBS;
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Gibco), 1% Penicillin/Streptomycin (Euroclone) supplemented with hy-
gromicin B 100µg/ml and blasticidin 15µg/ml. U-2OS shSCRAMBLE
and sh53BP1 were grown in Dulbecco’s Modified Eagle Medium (Gibco)
containing 10% Fetal Bovine Serum (FBS; Gibco) and 1% Penicillin/
Streptomycin (Euroclone) supplemented with puromycin 1µg/ml. In
U-2OS-SEC and HEK293-SEC, SpCas9 was induced with 1µg/ml doxycy-
cline for 24h before transfection. Plasmid all-in-one vectors px330A-1x2
and px330S-2, carrying Spcas9 gene and the sgRNAs cloning site, were
obtained from Dr. Takashi Yamamoto via Addgene (plasmids #58766
and # 58778 respectively [11]. sh53BP1 plasmid was purchased from
Sigma-Aldrich (Mission shRNA, NM_005657). siRNA against luciferase
(5′-CGUACGCGGAAUACUUCGATT-3′), CTIP (5′-UCCACAACAUAAUC-
CUAAU-3′) or BRCA1 (5′-CAGCUACCCUUCCAUCAUA-3′) were used for
transfection with Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturer’s instructions. NU7441 compound (a DNA-PKcs inhibitor)
was purchased from Selleckchem and was used at a concentration of
5µM for 24h after cell transfection with the all-in-one vectors. For re-
section experiments in Cas9-inducible stable cell lines, sgRNAs target-
ing DSB1 and DSB2 were synthesized and purchased from ThermoFisher
and used for transfection with Lipofectamine RNAiMAX (Invitrogen),
according to the manufacturer’s instructions. For experiment with cell
nucleofection with the all-in-one vectors, 10⁠6 U-2OS or HEK293T cells
were electroporated with Amaxa Nucleofector II, according to the man-
ufacturer’s instructions using the X-001 program and Q-001 respec-
tively.
2.2. Human genomic DNA extraction
U-2OS and HEK293T cells and their derivatives were grown on
6-well plates after transfection. At the indicated time points, cells where
trypsinized, washed in PBS and genomic DNA was extracted by Nucle-
oSpin⁠™ Tissue kit (Macherey-Nagel), according to the manufacturer’s
instructions. The day after, 15µl of genomic DNA (DNA concentration
is around 100ng/µl) were digested or mock with 20 units of BsrGI or
BamHI restriction enzymes (New England BioLabs) for 5h at 37°C. Di-
gested or mock DNA was purified and 5µl were used for the ddPCR re-
action.
2.3. Droplet digital PCR assay
The ddPCR reaction was assembled as follows: 5µl of genomic DNA
(approximately 50ng), 1X ddPCR⁠™ Supermix for Probes (no dUTP,
Bio-Rad), 900nM for each pair of primers, 250nM for each probe (HEX
and FAM, TaqMan probes) and dH⁠2O to 20µl per sample. We produced
droplets pipetting 20µl of the PCR reaction mix into single well of a uni-
versal DG8⁠™ cartridge for droplets generation (Bio-Rad). 70µl of droplet
generation oil were also added in each well next to the ones contain-
ing the samples. Cartridges were covered with DG8⁠™ droplet generator
gaskets (Bio-Rad) and then placed into the droplet generator (QX200 ⁠™,
Bio-Rad). After droplet generation, 40µl of emulsion were transferred
from the right well of the cartridge to a 96-well ddPCR plate (BioRad).
Before PCR reaction, 96-well PCR plates were sealed with peelable foil
heat seals at the PCR plate sealer machine (PX1⁠™, Bio-Rad).
PCR (T100⁠™ thermocycler, BioRad) was run using a ramp rate of
2.5°C/s between each step. First, Taq polymerase was activated at 95°C
for 5min and then 39 cycles of 95°C for 30s and 58.7°C for 1min
were made. At the end of the cycles, one additional cycle at 4°C for
5min and one at 90°C for 5min were made, then temperature was
held at 12°C. After the PCR, FAM and HEX fluorescence was read at
the droplet reader (QX200 ⁠™, BioRad) using QuantaSoft⁠™ software (Bio-
Rad). For each sample the number of droplets generated were on an
average of 15 000. The number of copies/µl of each target locus was
determined setting an empirical baseline threshold identical in all the
samples.
For the calculation of Cas9 cleavage efficiency (CE), we made the ra-
tio (r) between the number of copies of the locus across the Cas9 sites
(HEX1 and HEX2 probes) and a control locus on Chr. XXII (FAM probe)
in cells transfected with or without sgRNAs. We then calculated:
R= r⁠+⁠sgRNA/r⁠−⁠sgRNA
and the final CE value with the following equation:
% Cas9 cut efficiency (CE)=(1−R)*100%
For the measurement of ssDNA generated by the resection process
(% ssDNA, SS value), we calculated the ratio (r′) between the number
of copies nearby the DSB loci (335 bp from DSB1 and 364 bp from
DSB2, recognized by HEX3 and HEX4 probes respectively) and a control
non-target locus (NT locus) on Chr. XXII (FAM probe), with or without
sgRNA, digested or mock with BsrGI or BamHI restriction enzymes. The
absolute percentage of ssDNA was then calculated with the following
equation:
% ssDNA (SS)=[(r′⁠digested/r′⁠mock)⁠+sgRNA−(r′⁠digested/r′⁠mock)⁠−sgRNA] *100%
The final percentage of DSB resected (RES value) was calculated
with the formula:
RES=SS/CE
All the sequences of primers and probes used are listed in Table S1.
2.4. Real Time PCR assay
Real Time PCR analysis was performed as previously described [12].
In brief, 4µl of digested and undigested DNA was used as template in
a 20µl reaction containing 10µl 2x TaqMan Master mix (Genespin),
250nM of each probe and 450nM of each primer. % ssDNA (SS), % Cas9
cut efficiency (CE) and % DSB resected (RES) were calculated using the
formula described in [13].
2.5. Immunoblot analysis
For total protein extract preparation, cells were lysed in 1% SDS
sample buffer and protein samples, after loading normalization, were
analyzed by SDS-PAGE. Antibodies used in this study were the fol-
lowing: anti-FLAG (clone M2, Sigma-Aldrich), anti-53BP1 (Cell Sig-
naling), anti-GAPDH (Santa Cruz Biotechnology), anti-BRCA1 (Santa
Cruz Biotechnology), anti-CTIP (a kind gift from Dr. Pablo Huertas),
anti-Actin (Sigma-Aldrich).
3. Results and discussion
DSB resection is a key process to trigger HDR, favouring knock-in
outcomes in gene editing. Alternatively, NHEJ pathway promotes lim-
ited processing of the break, with addition/removal of one or few
bases (indels), often resulting in gene knock-out (Fig. 1A). Aiming to
verify and accurately quantify resection at Cas9-DSB, we developed a
ddPCR-based protocol. The rational of ddPCR is based on the parti-
tioning of DNA input molecules into thousands of nanoliter-sized uni-
form droplets that result in an end-point absolute quantification of
DNA targets after a standard PCR reaction [14]. Indeed, a ddPCR-based
method has been recently described to accurately and precisely measure
Cas9-induced cut efficiency in human cell lines [15]. We started from
a protocol originally developed in the model organism S. cerevisiae to
analyse DNA end resection of DSB induced by the homothallic nuclease
HO [16,17]. More recently, this was adapted to analyse DSBs induced
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Fig. 1. Cas9-induced DSB formation quantified by a ddPCR-based protocol.A. Schematic representation of the formation of knock-out/in outcomes by Cas9-induced DSB.B. Schematic
illustration of our ddPCR assay to calculate Cas9 cut efficiency (CE). HEX1 and HEX2 probes are designed downstream or across the selected Cas9-cleavage sites (DSB1, position 89 231
183 on chromosome I; DSB2, position 109 838 221 on chromosome I), whereas a FAM probe is designed in a non-target sequence (NT locus) on chromosome XXII. H1/2 and H5/6
primer pairs amplify a sequence across DSB1 and DSB2, respectively. F1/F2 primer pair amplifies a sequence within the NT locus.C. Genomic DNA was extracted from U-2OS cells and
digested or not with AsiSI restriction enzyme in vitro. Undigested and digested DNA were mixed at fixed proportion (e.g. 50% AsiSI digested DNA is obtained by mixing equal volumes of
undigested and digested DNA) and cleavage efficiency (CE) was measured by ddPCR and Real Time PCR (see Material and methods), comparing the obtained values with the theoretical
values. In the above plot HEX1 and FAM probes were used, whereas in the lower plot HEX2 and FAM probes were used. The mean ± SD values of two independent experiments are
plotted.D. Representative plots for droplets obtained by ddPCR with primer pair H1/H2, 9h after transfection with/without in vitro synthesized sgRNA1 of U-2OS-SEC cells, previously
treated with doxycycline for 24h to induce SpCas9 expression. Droplets are plotted based on their HEX and FAM fluorescence intensity. An empirical baseline threshold is applied to
distinguish negative and positive droplets.E. The graph shows the ratio of number of copies of HEX and FAM loci within the same samples described in (D).
by the restriction enzyme AsiSI (AsiSI-DSB) in U-2OS cells by real-time
PCR (RT-PCR) [12,18,19]. Here the protocol has been further modi-
fied to quantify the cut efficiency and the 5′-end resection of Cas9-DSB
through a novel and versatile ddPCR-based method (ddPCR assay at
DSB, or ddPaD). Among the several advantages of the ddPCR over the
RT-PCR, there are the high sensitivity and reproducibility of the results,
coupled with the use of internal references, without the need of stan-
dard curves [20]. Therefore, despite the droplet fluorescence-reading
step, overall ddPCR may allow to save time and reagents if compared to
RT-PCR (see Material and methods).
In order to set up the method, we chose two AsiSI cut sites on Chro-
mosome I, which were already proven to be resected by RT-PCR in
U-2OS cell line [12,18,19], to target with specific small guide RNA (sgR-
NA1 and 2) (Figs. 1B, S1 and S2). To verify if ddPCR would be accu-
rate enough to measure 100% cut efficiency (CE) for a completely cut
template, we performed an in vitro assay digesting or not the genomic
DNA with the AsiSI enzyme, which cuts in direct vicinity of the target
Cas9 sites. Before PCR reactions, digested and undigested samples were
mixed at fixed proportion. The empirical CE values determined both by
RT-PCR and ddPCR were in line with the expected theoretical values
(Fig. 1C). Remarkably, ddPCR gave more accurate and reproducible
measurements respect to RT-PCR, which is particularly evident
when decreasing the amount of amplifiable DNA (50–75% AsiSI in vitro
digested samples, Fig. 1C). This should be taken into consideration
when performing in vivo analysis, since cleavage induced by heterolo-
gous nucleases may be poorly efficient.
The results in Fig. 1C confirm the high reliability of ddPCR com-
pared to RT-PCR, and prompted us to use it to measure Cas9-DSB
formation and processing in vivo. At first, we transfected a derivative
U-2OS cell line (U-2OS-SEC) where SpCas9 gene is stably integrated in
the genome and controlled by a tet-OFF promoter [10], with in vitro
synthesized sgRNA1 and sgRNA2. At different hours after transfection,
CE was quantified using HEX-labelled probes across the Cas9 cleavage
sites (HEX1 and HEX2 for DSB1 and DSB2 loci, respectively) and a
FAM-labelled probe (FAM) on a reference non-target locus (NT locus)
on chromosome XXII (Fig. 1B). Using ddPCR to amplify the DSB and
NT loci, we found that the number of HEX droplets significantly de-
creased with respect to the FAM droplets once cells were transfected
with sgRNA1 and 2. The fraction of positive droplets is then used to
calculate the absolute amount of the target sequence (copy) [14], and
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the ratio between HEX and FAM copies is reported in a graph (see an
example for sgRNA1 at 9h in Fig. 1D, E). These and other results (data
not shown) indicate that Cas9 is cutting the selected DSB1 and DSB2
loci, but not the NT locus. Subsequently, using probes HEX3 and HEX4
we performed ddPCR to amplify a locus 335 bp nearby DSB1 and 364
bp nearby DSB2, after genomic DNA digestion with a selected restric-
tion enzyme (see details in Figs. 2A, S1, S2 and Material and methods).
The basic assumption is that once the resection of the 5′-end filament
starts, the exposed 3′-end ssDNA filament will be resistant to in vitro re-
striction digestion and therefore will be PCR amplified (Fig. 2A). No
Fig. 2. DSB processing in SpCas9 inducible cell lines quantified by a ddPCR-based protocol.A. Scheme of the strategy used to quantify 5′-end resection nearby a Cas9-DSB. Genomic DNA
is extracted and digested with a selected restriction enzyme, which cuts inside the genomic sequence between the primer pair (H3/H4 or H7/H8 for sequences 335bp nearby DSB1 or
364bp nearby DSB2, respectively). Synthetic HEX probes (HEX1 and HEX3 for DSB1 and HEX2 and HEX4 for DSB2) are used in the reaction to detect the selected sequence. In particular,
after restriction digestion, unresected (double-stranded) DNA sequence will be not amplified.B. Representative plots for droplets obtained by ddPCR with primer pair H7/H8, 9h after
transfection with/without in vitro synthesized sgRNA2 of U-2OS-SEC cells, previously treated with doxycycline for 24h to induce SpCas9 expression. Droplets are plotted based on their
HEX and FAM fluorescence intensity. An empirical baseline threshold is applied to distinguish negative and positive droplets.C. The graph shows the ratio of number of copies of HEX
and FAM loci within the same samples described in (B). Similar analysis as in (B) and (C) is shown for sgRNA1 in Fig. S3. These values will be used to calculate the percentage of ssDNA
(SS parameter) at the analysed locus (see Material and methods).D. U-2OS-SEC (Stably Expressing Cas9) cells were treated for 24h with doxycycline to induce SpCas9 expression. The
day after, cells were transfected with in vitro synthesized sgRNA1 and 2. Cells were harvested at the indicated time points and genomic DNA was extracted. Undigested or digested DNA
samples were analysed by ddPCR using HEX1-4 and FAM probes. The mean±SD of the CE, SS and RES (% DSB resected) values of two independent experiments are plotted.E. U-2OS-SEC
cells were seeded in 6-well plates and the day after CTIP or BRCA1 were silenced by siRNA. After 48h from siRNA transfection, SpCas9 was induced by doxycycline for 24h. The day after,
cells were transfected with sgRNA1 and 2 as in (D), and after 6h they were harvested for genomic DNA and protein lisate preparation. The mean±SD of the CE, SS and RES values of two
independent experiments are plotted.
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Fig. 3. DNA-PKcs activity and 53BP1 limit Cas9-induced DSB resection in transiently transfected cells.A. Resection of Cas9-induced DSB was analysed at DSB1 and DSB2 in U-2OS cells
transfected with all-in-one vectors expressing SpCas9±sgRNA1 and sgRNA2. Genomic DNA was extracted 24h after transfection and ddPCR was performed using appropriate primer pairs,
HEX1-4 and FAM probes on undigested or digested samples. The mean±SD of the CE, SS and RES values of four independent experiments are plotted. The protein level of SpCas9 in the
cells is shown in Fig. S3.B. Similar experiment as in (A) performed in HEK293T cell line. The protein level of SpCas9 in the cells is shown in Fig. S3.C. U-2OS cells were transfected as in
(A) and cells were treated or mock with NU7441 (5μM), a commercial DNA-PKcs inhibitor. Genomic DNA was extracted 24h after transfection and ddPCR was performed using HEX1, 3
and FAM probes on undigested or digested samples. The mean±SD of the CE, SS and RES values of four independent experiments are plotted. * p-value < 0.05, ** p-value < 0.01, ***
p-value < 0.001 according to the T-student test two-tailed.D. U-2OS cells stably expressing scramble shRNA or shRNA against 53BP1 gene were transfected with all-in-one vectors as in
(A). Genomic DNA was extracted 18h after transfection and ddPCR was performed using HEX1, 3 and FAM probes on mock or digested samples. The mean±SD of the CE, SS and RES
values of three independent experiments are plotted. * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001 according to the T-student test two-tailed. The protein level of 53BP1 in
the cells is shown in Fig. S4.
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tably, this method cannot distinguish the polarity of nucleolytic pro-
cessing of the 5′-end filament, which can occur through a bi-directional
process [21,22]. As such, at different hours after transfection with the
sgRNA1 and 2, and after restriction digestion, the number of HEX3 and
HEX4 positive droplets are still quantifiable, while after mock trans-
fection, their signals almost disappear (see examples at 9h in Figs. 2B
and S3A). Importantly, the number of FAM positive droplets at the ref-
erence NT locus reflects the amount of DNA in each sample and does
not significantly change in all the conditions. This value is then used
to calculate the ratio between the HEX and FAM positive copies (Figs.
2B–C and S3A–B). The data indicate that the nucleolytic processing of
the Cas9-DSB leads to the exposure of ssDNA at the analyzed loci. We
calculate the absolute percentage of ssDNA (SS value) at a specific lo-
cus as the ratio between the HEX and FAM positive amplicons with
or without the sgRNA, after mock sample normalization (see Material
and methods). We also calculate the CE values at different time points
after transfection as described in Material and methods. Then, the ra-
tio between the SS and the CE values will be hereafter defined as per-
centage of DSB resected (RES value). In Fig. 2D, we plotted the CE, SS
and RES values at DSB1 and DSB2 obtained in U-2OS-SEC cell line. We
also performed similar analysis in HEK293 derivative cell line [10], sta-
bly expressing SpCas9 (Fig. S3E). The same loci nearby the DSB1 and
DSB2 have been shown resected after AsiSI cutting and analyzed by
RT-PCR [12,18], thus validating our results by the new ddPCR approach
and clearly showing that the resection of Cas9-DSBs can be precisely
quantified, in different cell lines. Remarkably, in a separate experiment
in which we directly compared Cas9-DSB formation and processing in
U-2OS-SEC cells by ddPCR and RT-PCR, we observed that the two meth-
ods gave similar results (Fig. S3F). However, ddPCR was much more ac-
curate and reproducible, according to our previous assay (Fig. 1C).
To further confirm that the ssDNA formation at Cas9-DSB was due
to in vivo nucleolytic processing, we found that depletion of CTIP and
BRCA1 severely reduced SS and RES values (Fig. 2E), in agreement with
other studies [12,19,23]. Of note, using qPCR and different experimen-
tal scheme, others did not observe ssDNA decrease in BRCA1 deficient
cells (ref 12).
However, the isolation of a single-cell clone stably expressing SpCas9
is not always possible in a reasonable short experimental time frame
with all the cell lines of interest, particularly if they are primary cells
isolated from patients. Therefore, we applied our ddPCR-based method
to quantify formation and processing of Cas9-DSB induced by transient
transfection with all-in-one vectors [11], expressing both the SpCas9
and the sgRNAs. We transfected U-2OS and HEK293T cell lines with
vectors expressing SpCas9 with or without the sgRNA1 and 2, following
a standard electroporation procedure (see Material and methods). 24h
after transfection, we performed ddPCR reactions to determine the CE,
SS and RES values, as described above. The results indicate that both the
Cas9-DSB1 and 2 can be efficiently induced and resected even after a
transient transfection protocol, in the two different cell lines (Fig. 3A,B).
It is well known that the efficiency of knock-in mediated by HDR
is substantially lower compared with the efficiency of knock-out me-
diated by the NHEJ pathway. Suppressing NHEJ or enhancing HDR
has been demonstrated to promote the nuclease-mediated knock-in ef-
ficiency both in cultured cells and in model organisms [24]. Therefore,
we analyzed the efficiency of formation and resection of Cas9-DSB1 in
U-2OS cells after treatment with NU7441 (a commercial DNA-PKcs in-
hibitor), or after silencing the repair and regulatory factor 53BP1 [4].
24h after transfection, both the inhibition of DNA-PKcs and the silenc-
ing of 53BP1 enhance the SS and RES values (Fig. 3C,D). Importantly,
only the inhibition of DNA-PKcs increases the CE values, as a conse-
quence of NHEJ inhibition (Fig. 3C), confirming previous results ob-
tained with similar approaches [12,18].
Overall, the obtained results (particularly the results in Figs. 2E, 3C
and 3D) underline the high sensitivity of ddPaD method to quantify
Cas9-DSB formation and processing, suggesting a direct utility to fur-
ther characterize a critical step of the balance between NHEJ and HDR
outcome in gene editing, virtually in all cell types and organisms. More
in general, ddPaD can be applied to study DSB induced by all type of
nucleases that cut in defined loci in the genome. An interesting issue to
address in the near future regards the direct correlation between DSB
resection and HDR efficiency. This can be investigated at Cas9-DSBs in-
duced in a reporter cassette [25]. Indeed, the regulation of DSB resec-
tion is critical for accurate DSB repair, being an attractive target in sev-
eral basic and medical studies for the identification of novel therapeu-
tic approaches for cancer and other genome instability syndromes [7].
Very relevant for human health, we also propose that the possibility to
test the capability to efficiently resect a DSB by a reliable and sensitive
method may be utterly informative prior to set up appropriate gene edit-
ing protocols to correct pathologic mutations in a desired cell line and, if
applicable, in embryos for gene therapy. In fact, mutation in DSB repair
factors, cell cycle stage and other cellular features may affect Cas9-DSB
processing and editing [24]. Moreover, getting this information for a
specific cancer cell type may help to plan personalized therapy to sen-
sitize that specific tumor to pharmacologic-induced DSBs [6]. More in
general, we predict that ddPaD method may be useful for all the increas-
ing number of applications, in research and beyond, based on the Cas9
technology [26].
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